Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

BEACON-AA: Apixabano Com ou Sem Clopidogrel em Doentes com Acidente Vascular Cerebral com Fibrilhação Auricular e Aterosclerose Cerebral

15 de novembro de 2026 atualizado por: Yonsei University

Um Estudo Multicêntrico Prospetivo Randomizado para Avaliar a Eficácia do Apixabano e Clopidogrel na Prevenção do Acidente Vascular Cerebral Isquémico Recorrente em Doentes com Fibrilhação Auricular e Aterosclerose Cerebral

This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomly assigned in a 1:1 ratio to receive apixaban monotherapy or dual therapy with clopidogrel for 30 days. The primary outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30 (±5) days compared with baseline MRI, adjudicated by a central committee.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Although oral anticoagulants are effective in preventing cardioembolic stroke in patients with non-valvular atrial fibrillation (NVAF), a considerable proportion of ischemic strokes in these patients are caused by concomitant large artery atherosclerosis. Carotid or intracranial artery stenosis is present in a substantial number of patients with NVAF and is associated with a higher risk of recurrent cerebral infarction despite standard anticoagulation. In such patients, adding an antiplatelet agent to oral anticoagulation may theoretically reduce atherothrombotic events, but it also raises concern for increased bleeding risk. Recent clinical evidence on this issue remains limited, and the optimal antithrombotic strategy for patients with NVAF and coexisting symptomatic atherosclerotic stenosis has not been clearly established.

The BEACON-AA trial is a multicenter, randomized, open-label, blinded-endpoint (PROBE) study designed to compare the safety and efficacy of apixaban monotherapy versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation (NVAF) and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomized in a 1:1 ratio to receive apixaban alone or apixaban plus clopidogrel for 30 days, followed by apixaban monotherapy thereafter.

Brain MRI including diffusion-weighted and FLAIR sequences will be performed at baseline and at 30 ± 5 days to assess new or recurrent ischemic lesions. The primary efficacy outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee. Secondary efficacy outcomes include: 1) incidence of symptomatic ischemic stroke or transient ischemic attack within 90 days, 2) incidence of acute coronary syndrome within 90 days,3) cardiovascular mortality within 90 days, 4) composite major cardiovascular events within 90 days, 5) all-cause mortality within 90 days, 6) proportion of patients with modified Rankin Scale (mRS) 0-2 at 90 days, and 7) proportion of patients with mRS 0-3 at 90 days. The primary safety outcomes are: 1) incidence of major bleeding within 90 days, defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria and 2) incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE)) at 30 ± 5 days after randomization. All imaging and clinical events will be independently adjudicated by blinded central adjudication committees.

Tipo de estudo

Intervencional

Inscrição (Estimado)

586

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Young Dae Kim, M.D. Ph.D.
  • Número de telefone: 02-2228-1619
  • E-mail: NEURO05@YUHS.AC

Locais de estudo

      • Busan, Coréia do Sul
        • Recrutamento
        • Pusan National University Hospital
        • Contato:
          • Han-Jin Cho, Professor
          • Número de telefone: '+82--51-240-7000
          • E-mail: chohj75@gmail.com
      • Busan, Coréia do Sul
        • Recrutamento
        • Dong-A University Hospital
        • Contato:
          • Jung Hwa Seo, Professor
          • Número de telefone: +82-51-240-2000
          • E-mail: jhseo34@gmail.com
      • Chuncheon, Coréia do Sul
        • Recrutamento
        • Hallym University Chuncheon Sacred Heart Hospital
        • Contato:
      • Daegu, Coréia do Sul
        • Recrutamento
        • Keimyung University Dongsan Hospital
        • Contato:
      • Goyang, Coréia do Sul
        • Recrutamento
        • National Health Insurance Service Ilsan Hospital
        • Contato:
      • Incheon, Coréia do Sul
        • Recrutamento
        • Inha University Hospital
        • Contato:
      • Incheon, Coréia do Sul
        • Recrutamento
        • Gachon University Gil Medical Center
        • Contato:
          • Sang Hee Ha, Professor
          • Número de telefone: +82-1577-2299
          • E-mail: shha31@naver.com
      • Incheon, Coréia do Sul
        • Recrutamento
        • Catholic Kwandong University International St. Mary's Hospital
        • Contato:
          • Sang-Jun Ahn, Professor
          • Número de telefone: +82-1600-8291
          • E-mail: neuroan@gmail.com
      • Seoul, Coréia do Sul
        • Recrutamento
        • Samsung Medical Center
        • Contato:
      • Seoul, Coréia do Sul
        • Recrutamento
        • Seoul National University Hospital
        • Contato:
          • Keun-Hwa Jung, Professor
          • Número de telefone: +82-1588-5700
          • E-mail: jungkh@gmail.com
      • Seoul, Coréia do Sul
        • Recrutamento
        • Korea University Anam Hospital
        • Contato:
      • Seoul, Coréia do Sul
        • Recrutamento
        • Kangbuk Samsung Hospital
        • Contato:
      • Seoul, Coréia do Sul
        • Recrutamento
        • Ewha Womans University Seoul Hospital
        • Contato:
      • Seoul, Coréia do Sul
        • Recrutamento
        • Gangnam Severance Hospital
        • Contato:
          • Yo Han Jung, Professor
          • Número de telefone: +82-1599-6114
          • E-mail: YHJUNG@yuhs.ac
      • Seoul, Coréia do Sul
        • Recrutamento
        • Hanyang University Seoul Hospital
        • Contato:
      • Seoul, Coréia do Sul
        • Recrutamento
        • Kyung Hee University Hospital
        • Contato:
      • Seoul, Coréia do Sul
        • Recrutamento
        • Kyung Hee University Hospital at Gangdong
        • Contato:
          • Il Hyung Lee, Professor
          • Número de telefone: +82-1577-5800
          • E-mail: neu210@naver.com
      • Seoul, Coréia do Sul
        • Recrutamento
        • Inje University Sanggye Paik Hospital
        • Contato:
      • Seoul, Coréia do Sul
        • Recrutamento
        • Kangdong Sacred Heart Hospital
        • Contato:
      • Seoul, Coréia do Sul
        • Recrutamento
        • Yonsei University College of Medicine
        • Contato:
          • Young Dae Kim, Professor
          • Número de telefone: +82-2-2228-1619
          • E-mail: NEURO05@YUHS.AC
      • Yŏngin, Coréia do Sul
        • Recrutamento
        • Yongin Severance Hospital
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

19 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Adults aged 19 years or older at the time of enrollment.

  2. Patients with non-valvular atrial fibrillation (NVAF) documented by electrocardiography.

  3. Acute ischemic stroke confirmed by brain MRI (diffusion-weighted and FLAIR sequences), with last known well within 120 hours prior to randomization.

  4. Presence of clinically significant atherosclerosis in the cerebral or aortic arteries, meeting at least one of the following criteria:

    ① ≥30% stenosis in the relevant artery (the artery supplying the infarcted territory) demonstrated by CTA, MRA, or DSA - using the WASID criteria for intracranial arteries and NASCET criteria for extracranial arteries.

    ② High-risk atherosclerotic plaque features in the relevant artery demonstrated by CTA, MRA, or ultrasound, such as ulceration, intraplaque hemorrhage, mobile plaque, or a large lipid core (involving ≥25% of plaque cross-sectional area) on CTA/MRA, or ulceration, mobile plaque, or hypoechoic/echolucent plaque on ultrasound; or presence of branch artery occlusive disease (BAOD).

    ③ Complex aortic plaque (≥4 mm in thickness, mobile, or ulcerative) identified in the ascending aorta or aortic arch by transthoracic/transesophageal echocardiography or coronary CT angiography.

  5. Written informed consent provided by the participant or a legally authorized representative.

Exclusion Criteria:

  1. Presence of mechanical heart valves or rheumatic mitral stenosis.
  2. Requirement for antithrombotic agents other than apixaban and clopidogrel.
  3. Planned percutaneous coronary intervention, coronary artery bypass graft surgery, carotid endarterectomy, or intracranial stenting within 3 months after enrollment.
  4. Presence of mural thrombus in the heart confirmed by imaging.
  5. Renal impairment with creatinine clearance ≤25 mL/min.
  6. Severe hepatic impairment, including acute hepatitis, chronic active hepatitis, hepatic lesions or coagulopathy, hepatic failure, or laboratory evidence of AST/ALT >2× the upper limit of normal (ULN) or total bilirubin ≥1.5× ULN.
  7. Small-vessel occlusion (lacunar infarction) according to the TOAST classification.
  8. History within the past 30 days of gastrointestinal bleeding, vascular malformation of the brain or spinal cord, recent brain, spinal, or ophthalmologic surgery or trauma, esophageal varices, or intracranial hemorrhage at any time; or chronic regular use of NSAIDs (≥3 days per week for ≥2 consecutive weeks).
  9. Ischemic stroke occurring despite concurrent use of both NOAC and antiplatelet therapy.
  10. Planned surgery or high-bleeding-risk procedure within 3 months, or presence of active bleeding at enrollment.
  11. Anemia (hemoglobin < 8.0 g/dL) or thrombocytopenia (platelet count < 100,000/µL).
  12. Pre-stroke modified Rankin Scale (mRS) ≥ 2.
  13. Severe comorbid illness or malignancy not in complete remission with an expected life expectancy <1 year.
  14. Known hypersensitivity or allergy to apixaban or clopidogrel.
  15. Pregnant or breastfeeding women.
  16. Uncontrolled diabetes mellitus (HbA1c > 10.0%) or severe hypertension (systolic ≥ 220 mmHg or diastolic ≥ 120 mmHg).
  17. Concomitant use of strong CYP3A4 and P-glycoprotein inhibitors that can significantly increase apixaban exposure (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin).
  18. Concomitant use of strong CYP2C19 inducers that can enhance clopidogrel antiplatelet effect and increase bleeding risk (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort).
  19. Clinically significant mass effect due to space-occupying cerebral infarction, or patients expected to require decompressive craniectomy, including those with midline shift > 5 mm, loss of basal cisterns, herniation, fourth-ventricle compression, or obstructive hydrocephalus in posterior fossa infarcts.
  20. Intracranial hemorrhage or hemorrhagic transformation (PH1 or PH2) according to ECASS criteria.
  21. Participation in another interventional clinical trial within the past 30 days or concurrent participation in another interventional study (non-interventional observational or registry studies may be allowed at the investigator's discretion).
  22. Any other condition that, in the investigator's judgment, would make participation or continued involvement in the study inappropriate or infeasible.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Apixaban and Clopidogrel Combination Therapy

Participants receive apixaban(5mg twice daily, or 2.5mg twice daily if indicated) plus clopidogrel 75mg daily for 30days, followed by apixaban monotherapy thereafter.

Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.

Outros nomes:
  • Eliquis

Clopidogrel 75mg once daily for 30 days in combination with apixaban, then discontinued.

Outros nomes:
  • Plavix
Comparador Ativo: Apixaban Monotherapy

Participants receive apixaban 5mg(or 2.5mg if indicated) twice daily as monotherapy for 30 days and continue apixaban monotherapy thereafter.

Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.

Outros nomes:
  • Eliquis

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee
Prazo: At 30 ± 5 days after randomization

New ischemic lesions, either symptomatic or asymptomatic, identified on DWI/FLAIR at 30 (±5) days compared with baseline MRI, as adjudicated by a central adjudication committee.

At 30 ± 5 days after randomization

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Incidence of symptomatic ischemic stroke or transient ischemic attack (TIA)
Prazo: Within 90 days after randomization

Occurrence of new symptomatic ischemic stroke or transient ischemic attack confirmed by clinical and/or imaging criteria.

Within 90 days after randomization
Incidence of acute coronary syndrome (ACS)
Prazo: Within 90 days after randomization

Occurrence of acute coronary syndrome, including unstable angina or myocardial infarction, confirmed by standard diagnostic criteria.

Within 90 days after randomization
Cardiovascular mortality
Prazo: Within 90 days after randomization

Death due to fatal stroke, fatal myocardial infarction, or sudden death not clearly attributed to non-vascular causes.

Within 90 days after randomization
Composite major cardiovascular events
Prazo: Within 90 days after randomization

Composite of recurrent stroke (ischemic or hemorrhagic), acute coronary syndrome, or cardiovascular death.

Within 90 days after randomization
All-cause mortality
Prazo: Within 90 days after randomization

Death from any cause during the 90-day follow-up period.

Within 90 days after randomization
Proportion of patients with modified Rankin Scale (mRS) score 0-2
Prazo: At 90 days after randomization

Functional independence defined as mRS score of 0-2 at day 90.

At 90 days after randomization
Proportion of patients with modified Rankin Scale (mRS) score 0-3
Prazo: At 90 days after randomization

Favorable functional outcome defined as mRS score of 0-3 at day 90.

At 90 days after randomization
Incidence of major bleeding events according to the ISTH criteria
Prazo: Within 90 days after randomization

Major bleeding events defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria, including fatal bleeding, symptomatic intracranial hemorrhage, intraocular bleeding causing vision loss, bleeding resulting in inability to perform usual activities, bleeding requiring transfusion of ≥2 units of whole blood or red cells, or bleeding leading to hospitalization.

Within 90 days after randomization
Incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE))
Prazo: At 30 ± 5 days after randomization

Newly developed asymptomatic cerebral hemorrhages identified on MR-Diffusion/FLAIR/SWI(or GRE) performed 30 ± 5 days after randomization.

At 30 ± 5 days after randomization

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

14 de julho de 2026

Conclusão Primária (Estimado)

1 de julho de 2029

Conclusão do estudo (Estimado)

31 de agosto de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

14 de novembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de novembro de 2025

Primeira postagem (Real)

19 de novembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 4-2025-0697

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .